Fig. 2.

miR-137 regulates the lipid metabolism of melanoma cells. a miR-137 overexpression significantly suppressed the erastin- and RSL3-induced lipid formation. Indicated cells were treated with erastin (5 µM in A375, 10 µM in G-361) or RSL3 (0.1 µM in A375, 0.5 µM in G-361) for 24 h. The lipid formation was measured by MDA assay. Data shown represent mean ± SD from three independent experiments. **p < 0.01. b miR-137 antagomirs significantly increased the erastin- and RSL3-induced lipid formation. Indicated cells were treated with erastin (5 µM in A375, 10 µM in G-361) or RSL3 (0.1 µM in A375, 0.5 µM in G-361) for 24 h. The lipid formation was measured by MDA assay. Data shown represent mean ± SD from three independent experiments. **p < 0.01. c Overexpression of miR-137 significantly suppressed erastin- and RSL3-induced lipid ROS level as assessed by flow cytometry using C11-BODIPY. Indicated cells were treated with erastin (5 µM in A375, 10 µM in G-361) or RSL3 (0.1 µM in A375, 0.5 µM in G-361) for 24 h. d Cells transfected with miR-137 antagomirs showed increased lipid ROS level as assessed by BODIPY-C11 staining. Indicated cells were treated with erastin (5 µM in A375, 10 µM in G-361) or RSL3 (0.1 µM in A375, 0.5 µM in G-361) for 24 h. e, f The expression levels of miR-137 influences the Fe²⁺ accumulation in erastin or RSL3-treated A375 and G-361 cells. Indicated cells were treated with erastin (5 µM in A375, 10 µM in G-361) or RSL3 (0.1 µM in A375, 0.5 µM in G-361) for 24 h and the intracellular Fe²⁺ was assayed. Data shown represent mean ± SD from three independent experiments. *p < 0.05